Saturday, November 14, 2026

Enterprise AI deployments shift to production as infrastructure spending accelerates

Enterprises are moving AI workloads from experimentation to production environments, driving demand for hybrid cloud infrastructure and secure deployment platforms. Cisco, Red Hat, and Supermicro are responding with enterprise-grade AI systems designed for scale, while financial services firms like FIS launch AI-powered products.

From our archive, published before source-traceability. How we work

Enterprise AI deployments shift to production as infrastructure spending accelerates
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Enterprise AI adoption is transitioning from pilot projects to production deployments, requiring new infrastructure investments and security frameworks.

Cisco is prioritizing the move from AI experimentation to production environments. "We're focused on helping customers move AI from experimentation to production, securely, at scale," said Jeremy Foster, Cisco executive. The shift reflects growing enterprise confidence in AI technologies after years of testing.

Intel's Justin Boitano described the infrastructure challenge: "Enterprises are building AI factories that turn data into intelligence at scale during inference." These AI factories require dedicated hardware and software stacks optimized for production workloads rather than research environments.

Red Hat's Brian Stevens emphasized hybrid deployment: "The future of enterprise AI will be defined by its ability to operate autonomously across the hybrid cloud." Most enterprises run workloads across on-premises data centers and multiple cloud providers, requiring AI platforms that work consistently across environments.

Supermicro and Red Hat announced expanded hardware certification. "Supermicro has an extensive portfolio of Red Hat-certified systems dedicated to delivering AI infrastructure," said Vik Malyala, Supermicro executive. The certification ensures enterprises can deploy AI workloads with vendor support guarantees.

Financial services shows production AI deployment momentum. FIS launched AI-powered banking products in October 2025, moving beyond internal experimentation to customer-facing applications. Banks are deploying AI for fraud detection, customer service automation, and credit risk assessment.

The Magnificent 7 tech companies increased AI infrastructure investment projections for 2026, signaling continued buildout of enterprise-grade data center capacity. This capital expenditure supports both cloud AI services and on-premises deployment options for regulated industries.

Production AI deployments require different infrastructure than research environments: higher reliability standards, security compliance certifications, multi-region redundancy, and integration with existing enterprise systems. Vendors are adapting products to meet these requirements as experimental budgets convert to production spending.

In this story

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com